Phase 3 trial in 44 adolescents with symptomatic obstructive HCM: mavacamten reduced Valsalva LVOT gradient at week 28 vs placebo (-48.5 vs -0.5 mm Hg; difference -48.0); adverse events were similar.
RCTn = 44
Rossano et al. Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy